FATE Key Statistics, Chart & Performance
The current stock price of FATE is 0.9832 USD. In the past month the price decreased by -4.54%. In the past year, price decreased by -45.38%.
FATE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.31 | 406.04B | ||
| AMGN | AMGEN INC | 15.03 | 176.99B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.14 | 115.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.19 | 81.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 778.92 | 52.48B | ||
| INSM | INSMED INC | N/A | 37.13B | ||
| NTRA | NATERA INC | N/A | 31.74B | ||
| BIIB | BIOGEN INC | 10.54 | 25.88B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.8 | 21.37B | ||
| INCY | INCYTE CORP | 15.41 | 19.42B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About FATE
Company Profile
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 181 full-time employees. The company went IPO on 2013-10-01. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Company Info
FATE THERAPEUTICS INC
12278 Scripps Summit Drive
San Diego CALIFORNIA 92121 US
CEO: J. Scott Wolchko
Employees: 181
Phone: 18588751803
FATE THERAPEUTICS INC / FATE FAQ
Can you describe the business of FATE THERAPEUTICS INC?
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 181 full-time employees. The company went IPO on 2013-10-01. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
What is the current price of FATE stock?
The current stock price of FATE is 0.9832 USD. The price decreased by -1.43% in the last trading session.
Does FATE stock pay dividends?
FATE does not pay a dividend.
What is the ChartMill technical and fundamental rating of FATE stock?
FATE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists FATE stock?
FATE stock is listed on the Nasdaq exchange.
How is the valuation of FATE THERAPEUTICS INC (FATE) based on its PE ratio?
FATE THERAPEUTICS INC (FATE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.32).
What is the ownership structure of FATE THERAPEUTICS INC (FATE)?
You can find the ownership structure of FATE THERAPEUTICS INC (FATE) on the Ownership tab.
FATE Technical Analysis
FATE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FATE. The financial health of FATE is average, but there are quite some concerns on its profitability.
FATE Financial Highlights
Over the last trailing twelve months FATE reported a non-GAAP Earnings per Share(EPS) of -1.32. The EPS increased by 20% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.42% | ||
| ROE | -66.69% | ||
| Debt/Equity | 0 |
FATE Forecast & Estimates
18 analysts have analysed FATE and the average price target is 5.04 USD. This implies a price increase of 412.95% is expected in the next year compared to the current price of 0.9832.
For the next year, analysts expect an EPS growth of 28.57% and a revenue growth -52.5% for FATE